NCT01326598已完成不适用
Effectiveness of V-Go™ for Patients With Diabetes in a Real-world Setting: A Long-term, Prospective, Observational Registry (SIMPLE)
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 270
- 试验地点
- 25
- 主要终点
- The primary objective is to compare change of average glycemic control as measured by A1C from baseline to the end of V-Go use for the whole cohort as well as each of the five categories of baseline treatment.
研究概览
简要总结
The aim of the present study is to observe glycemic control, dose requirements, hypoglycemia risk, other possible adverse effects and weight changes, as well as to compare these parameters to prior treatment when patients with type 2 diabetes are initiated and treated using V-Go during circumstances as close to normal clinical practice as possible.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 21 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Diagnosed type 2 diabetes mellitus for at least 12 months.
- •Must be and have been in stable treatment for at least a month within each of the following diabetes medication regimens:
- •OADs only,
- •OADs in combination with either exenatide, pramlintide, liraglutide (collectively termed "incretin mimetics") without receiving insulin,
- •Once or twice daily injection of an intermediate or long acting insulin (insulin NPH, insulin detemir or insulin glargine) with or without OADs and/or an incretin.
- •One to three daily injections of premix insulin (human insulin 70/30, insulin lispro 75/25 or insulin aspart 70/30) with or without OADs and/or an incretin.
- •Any insulin therapy with three or more insulin injections a day with or without OADs (MDI).
- •Must be willing to self monitor glucose at least twice a day.
- •The patient must be willing and able in the opinion of the investigator to try V-Go as therapy.
- •Age between 21 and 80 years old, inclusive.
- •A1C greater than or equal to 7.0%.
排除标准
- •Acute infection with fever.
- •Serum creatinine > 3.0 mg/dl if not on metformin, or if on metformin for females creatinine > 1.4 mg/dl, for males creatinine > 1.5 mg/dl within the last 6 months.
- •Pregnancy, intention to become pregnant or failure to agree to use adequate contraceptive measures during the trial for females of current reproductive potential.Medically acceptable contraceptives include: (1) surgical sterilization (such as tubal ligation or hysterectomy), (2) approved hormonal contraceptives (pills, patches, implants, or injections), (3) barrier methods (condom, diaphragm) used with spermicide, or (4) intrauterine device (IUD). Contraceptive measures such as "Plan B™", for emergency use after unprotected sex, are not acceptable methods for routine use. A lifestyle of abstinence from sexual activity is an acceptable means of contraception. If currently abstinent, the subject must agree to use a double-barrier method as described above if they become sexually active during the study period.
- •Any medical history of malignant melanoma or breast cancer.
- •Medical history of any other cancers within the last five years except adequately treated basal cell carcinoma or cervical carcinoma in-situ.
- •History of alcohol or drug abuse within the last year.
- •Any medical condition that in the opinion of the investigator may preclude safe and successful completion of the trial.
- •Participation in other clinical trials involving receipt of investigational drug that cannot be disclosed within the last 30 days.
- •Unwillingness and/or inability to comply with study procedures.
- •Require regular adjustments or modifications to the basal rate during a 24-hour period, or if the amount of insulin used at meals require adjustments of less-than 2-Unit increments.
- •History of hypersensitivity or hyperreactivity to adhesives.
结局指标
主要结局
The primary objective is to compare change of average glycemic control as measured by A1C from baseline to the end of V-Go use for the whole cohort as well as each of the five categories of baseline treatment.
时间窗: 12 month
次要结局
- To describe the incidence of hypoglycemia in participants as measured by blood glucose of <70 mg/dl.(12 month)
- How well the participants follow their doctors prescriptions for diabetes care.(12 month)
- To describe insulin dose requirements from the beginning to the end of the study , and concomitant drugs to lower blood glucose.(12 month)
- Glycemic control is measured by the HbA1C from the beginning of the study to the end.(12 month)
- Number of Participants with adverse events.(12 month)
- To describe changes in participants' weight from the beginning to the end of the study.(12 month)
研究者
研究点 (25)
Loading locations...
相似试验
已完成
4 期
Effectiveness of Glucose Control, β Cell Function in Response to Short-term Insulin Pump Therapy in Type 2 DiabetesDiabetes Mellitus, Type 2NCT03509324Sun Yat-sen University67
Unknown
不适用
The Management of Glucose Control and Hypoglycemic Prevention Using Continuous Glucose Monitoring System in Patients With Type 1 DiabetesType 1 DiabetesNCT04684030Yonsei University60
招募中
不适用
Prospective evaluation of diabetes/ impaired glucose tolerance and insulin resistance among patients with endometrial cancerAtypical endometrial hyperplasia Endometrial cancerJPRN-UMIN000013804Graduate School of Medicine, Chiba University300
尚未招募
3 期
Comparison of efficacy and safety of different doses of metformin in women with gestational diabetes mellitusCTRI/2023/11/059803All India Institute of Medical Sciences New Delhi
已完成
1 期
Safety Study of BMS-903452 in Healthy Subjects (Panel 1-7) & Relative Bioavailability of the Crystalline and Amorphous Forms of BMS-903452 [Panels 4, 6, 11 & 12(Part A)], and Subjects With Type 2 Diabetes Mellitus (Part B)DiabetesNCT01240980Bristol-Myers Squibb104